The FDA has approved Moderna's mFLUSIVA, an mRNA-based flu vaccine for adults 50 and older. The approval marks the first seasonal flu vaccine using messenger RNA technology.
mFLUSIVA joins Moderna's existing portfolio of mRNA vaccines following its success with COVID-19 shots. The vaccine targets four influenza strains and is designed to provide immunity for the upcoming flu season.
The approval process faced delays and scrutiny from regulators, who requested additional data before greenlit the shot. Moderna addressed FDA concerns and submitted supplemental information to support the vaccine's safety and efficacy profile.
The company expects to begin distribution shortly. Healthcare providers can administer mFLUSIVA alongside other vaccines approved for older adults.
Moderna positions the mRNA platform as an advantage for rapid vaccine development and potential updates to match circulating flu variants. The approval expands options for flu prevention beyond traditional egg-based and cell-cultured vaccines currently available.
The shot enters a competitive flu vaccine market dominated by established manufacturers. Uptake will depend on healthcare provider adoption and patient acceptance of the newer technology.
Ukrainian military strikes on warehouses operated by Russia's largest e-commerce platform Wildberries are disrupting operations for tens of thousands of small businesses dependent on the platform.
Truth Social's parent company is refocusing on its media business and a $6 billion merger with TAE, pulling back from cryptocurrency partnerships while exploring a paid API for premium access to posts.
The US Office of the Comptroller of the Currency has denied Dutch fintech Bunq's application for a national bank charter, citing insufficient clarity on the company's US expansion strategy.
Restart, a gaming media site launched in late 2024 and sponsored by Walmart, has laid off its entire editorial team. The cuts were announced Friday by former editor-in-chief Brandy Berthelson.